	Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events. J Immunother Cancer Gente K, Diekmann L, Daniello L, Will J, Feisst M, Olsavszky V, Günther J, Lorenz HM, Souto-Carneiro MM, Hassel JC, Christopoulos P, Leipe J. PMID: 37730272 [PubMed - in process]
	Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis. Lung Cancer Parra-Medina R, Pablo Castañeda-González J, Montoya L, Paula Gómez-Gómez M, Clavijo Cabezas D, Plazas Vargas M. PMID: 37729688 [PubMed - as supplied by publisher]
	Should we be screening for COPD? - looking through the lens of lung cancer screening. Expert Rev Respir Med Young RP, Scott RJ. PMID: 37728077 [PubMed - as supplied by publisher]
	Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes. Front Pharmacol Xu X, Dai F, Mao Y, Zhang K, Qin Y, Zheng J. PMID: 37727388 [PubMed]
	Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer. Front Oncol Wang F, Xia T, Li Z, Gao X, Fang X. PMID: 37727216 [PubMed]
	Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer. J Transl Med Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, Lumet G, Ceccarelli M, Birnbaum D, Bedognetti D, Mamessier E, Barlesi F, Bertucci F, Tomasini P. PMID: 37726776 [PubMed - in process]
	Sleep disturbances and the risk of lung cancer: a meta-epidemiological study. BMC Cancer Zhou T, Wang Z, Qiao C, Wang S, Hu S, Wang X, Ma X, Wang D, Li J, Li Z, Hou W. PMID: 37726707 [PubMed - in process]
	An Update on Potential Molecular Biomarkers of Dietary Phytochemicals Targeting Lung Cancer Interception and Prevention. Pharm Res Peter RM, Chou PJ, Shannar A, Patel K, Pan Y, Dave PD, Xu J, Sarwar MS, Kong AT. PMID: 37726406 [PubMed - as supplied by publisher]
	Lobar or sublobar resection for early-stage second primary lung cancerâ€‰â‰¤â€‰3Â cm in size: a SEER population-based study. J Cancer Res Clin Oncol Zhao K, Xia C, Qiu M, Yang Z, Cui T, Song T, Li S, Mei H, Zheng Y, Wang H. PMID: 37725243 [PubMed - as supplied by publisher]
	Potential of ChatGPT and GPT-4 for Data Mining of Free-Text CT Reports on Lung Cancer. Radiology Fink MA, Bischoff A, Fink CA, Moll M, Kroschke J, Dulz L, Heußel CP, Kauczor HU, Weber TF. PMID: 37724963 [PubMed - in process]
	Incidence and Survival for Patients Diagnosed With Breast, Colorectal, and Lung Cancer in an Integrated System. Perm J Hahn EE, Ritzwoller DP, Munoz-Plaza CE, Gander J, Kushi LH, McMullen C, Oshiro C, Roblin DW, Wernli KJ, Staab J. PMID: 37724894 [PubMed - as supplied by publisher]
	Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis. Aging (Albany NY) Lin Y, Jiang W, Su CY, Pan XB. PMID: 37724893 [PubMed - as supplied by publisher]
	Nomogram based on clinical characteristics and radiological features for the preoperative prediction of spread through air spaces in patients with clinical stage IA non-small cell lung cancer: a multicenter study. Diagn Interv Radiol Wang Y, Lyu D, Zhang D, Hu L, Wu J, Tu W, Xiao Y, Fan L, Liu S. PMID: 37724737 [PubMed - as supplied by publisher]
	The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer Med Zhang S, Yang L, Yang Y, Yang G, Xu H, Niu X, Wang Y. PMID: 37723846 [PubMed - as supplied by publisher]
	Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. Cancer Med Chen K, Xu Y, Huang Z, Yu X, Hong W, Li H, Xu X, Lu H, Xie F, Chen J, Xu Y, Fan Y. PMID: 37723837 [PubMed - as supplied by publisher]
	Comparative analysis of methodologies for predicting overall survival in patients with non-small cell lung cancer based on the number and rate of resected positive lymph nodes: A study based on the SEER database for 2010 through 2019. Clin Respir J Guo Q, Hu S, Wang S, Su L, Zhang W, Xu J, Wei Y. PMID: 37723579 [PubMed - as supplied by publisher]
	Medico-economic impact of thoracoscopy versus thoracotomy in lung cancer: multicentre randomised controlled trial (Lungsco01). BMC Health Serv Res Soilly AL, Aho Glélé LS, Bernard A, Abou Hanna H, Filaire M, Magdaleinat P, Marty-Ané C, Tronc F, Grima R, Baste JM, Thomas PA, Richard De Latour B, Pforr A, Pagès PB. PMID: 37723516 [PubMed - indexed for MEDLINE]
	Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review. Semin Oncol Kim J, Jeong C, Lee J, Ha J, Baek KH, Kim S, An TJ, Park CK, Yoon HK, Lim JU. PMID: 37723018 [PubMed - as supplied by publisher]
	Induction Chemoimmunotherapy with Surgery versus Concurrent Chemoradiation followed by Immunotherapy for Stage III-N2 Non-small Cell Lung Cancer. J Thorac Cardiovasc Surg Kumar A, Srinivasan D, Potter A, Mathey-Andrews C, Lanuti M, Martin LW, Jeffrey Yang CF. PMID: 37722622 [PubMed - as supplied by publisher]
	Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial. Lung Cancer Garcia Campelo MR, Wan Y, Lin HM, Chen T, Shen J, Zhang P, Camidge DR. PMID: 37722340 [PubMed - as supplied by publisher]

Articles 1 - 20 / 135961

Page 1 of 6799



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy